Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization Of Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

NCT04902833 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04902833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization Of Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms
Lead sponsor
Massachusetts General Hospital
Phase
Observational
Overall status
Completed
Start date
February 1, 2022
Completion date
February 1, 2026
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, clonal cytopenia of undetermined significance, clonal myeloid neoplasm, hereditary hemolytic anemia, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm, myeloproliferative neoplasm, other clonal myeloid neoplasm, pyruvate kinase deficiency, pyruvate kinase deficiency anemia, unexplained coombs-negative non-immune hemolytic anemia